150 related articles for article (PubMed ID: 30139779)
1. Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD.
Lazaar AL; Miller BE; Tabberer M; Yonchuk J; Leidy N; Ambery C; Bloomer J; Watz H; Tal-Singer R
Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30139779
[No Abstract] [Full Text] [Related]
2. CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial.
Lazaar AL; Miller BE; Donald AC; Keeley T; Ambery C; Russell J; Watz H; Tal-Singer R;
Respir Res; 2020 Jun; 21(1):149. PubMed ID: 32532258
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects.
Miller BE; Mistry S; Smart K; Connolly P; Carpenter DC; Cooray H; Bloomer JC; Tal-Singer R; Lazaar AL
BMC Pharmacol Toxicol; 2015 Jun; 16():18. PubMed ID: 26092545
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Safety, Tolerability, Pharmacokinetics, and Food Effect of Danirixin Hydrobromide Tablets in Japanese Healthy Elderly Participants.
Iida T; Matsuzawa Y; Ogura H; Nagakubo T; Wakamatsu A; Ambery C; Miller BE; Lazaar AL; Numachi Y
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1081-1087. PubMed ID: 31056840
[TBL] [Abstract][Full Text] [Related]
5. Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2.
Busch-Petersen J; Carpenter DC; Burman M; Foley J; Hunsberger GE; Kilian DJ; Salmon M; Mayer RJ; Yonchuk JG; Tal-Singer R
J Pharmacol Exp Ther; 2017 Aug; 362(2):338-346. PubMed ID: 28611093
[TBL] [Abstract][Full Text] [Related]
6. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils.
Pedersen F; Waschki B; Marwitz S; Goldmann T; Kirsten A; Malmgren A; Rabe KF; Uddin M; Watz H
Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29449427
[No Abstract] [Full Text] [Related]
8. Evidence on the identity of the CXCR2 antagonist AZD-5069.
Norman P
Expert Opin Ther Pat; 2013 Jan; 23(1):113-7. PubMed ID: 22992174
[TBL] [Abstract][Full Text] [Related]
9. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
Kaur M; Singh D
J Pharmacol Exp Ther; 2013 Oct; 347(1):173-80. PubMed ID: 23912333
[TBL] [Abstract][Full Text] [Related]
11. Walking a tightrope: targeting neutrophils to treat chronic obstructive pulmonary disease.
Aaron SD
Am J Respir Crit Care Med; 2015 May; 191(9):971-2. PubMed ID: 25932758
[No Abstract] [Full Text] [Related]
12. Evaluation of WO2012080456 and WO2012080457; Boheringer Ingleheim's first CXCR2 antagonists.
Norman P
Expert Opin Ther Pat; 2013 Mar; 23(3):383-8. PubMed ID: 23321068
[TBL] [Abstract][Full Text] [Related]
13. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2.
Traves SL; Smith SJ; Barnes PJ; Donnelly LE
J Leukoc Biol; 2004 Aug; 76(2):441-50. PubMed ID: 15155777
[TBL] [Abstract][Full Text] [Related]
14. Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.
Seiberling M; Kamtchoua T; Stryszak P; Ma X; Langdon RB; Khalilieh S
Int Immunopharmacol; 2013 Oct; 17(2):178-83. PubMed ID: 23791619
[TBL] [Abstract][Full Text] [Related]
15. The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists.
Porter DW; Bradley M; Brown Z; Charlton SJ; Cox B; Hunt P; Janus D; Lewis S; Oakley P; O'Connor D; Reilly J; Smith N; Press NJ
Bioorg Med Chem Lett; 2014 Aug; 24(15):3285-90. PubMed ID: 24974342
[TBL] [Abstract][Full Text] [Related]
16. Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists.
Ho KK; Auld DS; Bohnstedt AC; Conti P; Dokter W; Erickson S; Feng D; Inglese J; Kingsbury C; Kultgen SG; Liu RQ; Masterson CM; Ohlmeyer M; Rong Y; Rooseboom M; Roughton A; Samama P; Smit MJ; Son E; van der Louw J; Vogel G; Webb M; Wijkmans J; You M
Bioorg Med Chem Lett; 2006 May; 16(10):2724-8. PubMed ID: 16540318
[TBL] [Abstract][Full Text] [Related]
17. Sildenafil improves six-minute walk distance in chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
Rao RS; Singh S; Sharma BB; Agarwal VV; Singh V
Indian J Chest Dis Allied Sci; 2011; 53(2):81-5. PubMed ID: 21545068
[TBL] [Abstract][Full Text] [Related]
18. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
Blanco I; Gimeno E; Munoz PA; Pizarro S; Gistau C; Rodriguez-Roisin R; Roca J; Barberà JA
Am J Respir Crit Care Med; 2010 Feb; 181(3):270-8. PubMed ID: 19875684
[TBL] [Abstract][Full Text] [Related]
19. Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial.
Llanos-Paez C; Ambery C; Yang S; Tabberer M; Beerahee M; Plan EL; Karlsson MO
AAPS J; 2021 Jun; 23(4):79. PubMed ID: 34080077
[TBL] [Abstract][Full Text] [Related]
20. Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD.
Holverda S; Rietema H; Bogaard HJ; Westerhof N; Postmus PE; Boonstra A; Vonk-Noordegraaf A
Pulm Pharmacol Ther; 2008; 21(3):558-64. PubMed ID: 18342559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
